APEPTICO completes a EUR 3.4 million financing round

16th May, 2012, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced completion of a EUR 3.4 million financing round. This equity financing combined existing and new private and institutional investors, as well as a research grant from the Austrian Research Promotion Agency (FFG).

A financing contribution of EUR 2 million is shared by institutional investors “The BioScience Venture Group”, “V+ GmbH & Co Fonds 2 KG” and “V+ GmbH & Co Fonds 3 KG”, and by private investors from Germany, Switzerland and the USA. Based on a previous and substantial capital increase in the year 2011, APEPTICO had already secured a research grant of EUR 1.4 million from the Austrian Research Promotion Agency (FFG) by the end of 2011.
Dr. Bernhard Fischer, CEO of APEPTICO commented: “We are delighted to have secured our third equity financing with an international syndicate of venture capital, private investors and the FFG. This round C financing enables us to continue the clinical development of our lead peptide AP301. AP301 will be assessed in a “proof of concept” study in intensive care patients to investigate the clinical effect of repetitive orally inhaled doses of AP301 on alveolar liquid clearance in acute lung injury.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.